Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Krueger

Dermatology New York, NY Medical Doctor

NPI 1821307703 CMS profile 870655

1230 York Ave, New York, NY 10065

Open in the dashboard

General payments

$671,913

678 records reported · program years 2019–2025

Research payments

$319,955

Paid to them · 26 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,638,343 paid to institutions, not to them · program years 2019–2025

Through program year 2025, James Krueger of New York, NY is reported in the CMS Open Payments database as having received $671,913 across 678 general payments and $319,955 in research payments paid to them. Separately, studies naming them as principal investigator received $5,638,343 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $83,686 80
2025 Research $1,860 2
2024 General $67,498 133
2023 General $121,238 102
2022 General $109,509 108
2022 Research $4,280 3
2021 General $106,636 62
2021 Research $259 1
2020 General $58,017 31
2020 Research $11,791 10
2019 General $125,329 162
2019 Research $301,766 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Krueger
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to James Krueger were reported at $83,686. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year James Krueger Dermatology median Middle half National median
2019 $125,329 $454 $129–$1,240 $163
2020 $58,017 $235 $81–$756 $114
2021 $106,636 $377 $108–$1,108 $132
2022 $109,509 $514 $143–$1,391 $149
2023 $121,238 $607 $159–$1,674 $160
2024 $67,498 $751 $204–$1,903 $164
2025 $83,686 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $103,788 64 payments
  2. AbbVie, Inc. $76,733 122 payments
  3. Boehringer Ingelheim International GmbH $56,744 74 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $52,110 24 payments
  5. Janssen Global Services, LLC $45,684 39 payments
  6. Ucb SA $43,480 29 payments
  7. Janssen Biotech, Inc. $42,304 61 payments
  8. Novartis Pharmaceuticals Corporation $37,421 42 payments
  9. Amgen Inc. $31,771 57 payments
  10. Janssen Scientific Affairs, LLC $23,369 4 payments
  11. Other $158,510 162 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $547,059 204 payments
  2. Travel and Lodging $61,356 206 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $51,487 33 payments
  4. Food and Beverage $7,676 232 payments
  5. Honoraria $3,310 2 payments
  6. Education $1,025 1 payment
Products named General payments · program years 2019–2025
  1. TREMFYA $98,457 92 payments
  2. SPEVIGO $30,193 43 payments
  3. COSENTYX $26,853 15 payments
  4. Enbrel Inflammation $15,273 13 payments
  5. SKYRIZI $9,446 5 payments
  6. SOTYKTU $8,251 4 payments
  7. NO PRODUCT DISCUSSED $7,995 2 payments
  8. SILIQ $7,347 3 payments
  9. Enbrel Inflammation $7,271 4 payments
  10. TARPEYO $5,000 2 payments
  11. Other $16,600 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Bausch Health US, LLC $296,800 3 payments
  2. Novartis Pharmaceuticals Corporation $9,269 13 payments
  3. Pfizer Inc. $7,670 4 payments
  4. Regeneron Pharmaceuticals, Inc. $3,044 2 payments
  5. Roche TCRC, Inc. $1,860 2 payments
  6. Eli Lilly and Company $1,313 2 payments

Records

704 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record